Skip to main content

Table 2 Descriptive of the mean cost and QALY along with their incremental data of comparison between GLP1a vs DPP4i

From: Meta-analysis of economic evaluation studies: data harmonisation and methodological issues

Author

Cost

QALY

ICER

Currency

GLP1

DPP4i

ΔC

GLP1

DPP4i

ΔE

 

Sinha [33]

US $

170,799

167,163

3636

15.2998

15.3335

-0.0337

-107,893

Davies [34]

£

21,793 ± 544

19,951 ± 521

1842 ± 751

7.52 ± 0.11

7.34 ± 0.11

0.19 ± 0.15

10,158

Guillermin [35]

US $

55,647

57,862

-2215

9.56 ± 0.12

9.28 ± 0.12

0.284 ± 0.172

-7799

Lee [36]

US $

81,444 ± 1079

76,262 ± 1061

5182

8.825 ± 0.117

8.624 ± 0.115

0.201

31,488

Mezquita-Raya[37]

€

54,684 ± 1250

52,387 ± 1346

2297

9.04 ± 0.13

8.87 ± 0.11

0.17

13,266

Steen-Carlsson [38]

SEK

1,360,715

1,304,092

56,624

10.53

10.15

0.38

154,226

Perez [39]

€

56,628 ± 1323

52,450 ± 1394

4177

9.239 ± 0.121

8.838 ± 0.121

0.4

10,436

Bruhn [40]

US $

140,806 ± 1948

138,583 ± 2071

2223

9.618 ± 0.125

9.517 ± 0.130

0.101

22,094

Roussel [41]

€

43,031 ± 1532

40,472 ± 1513

2558 (2427,2689) a

10.09 ± 0.13

9.84 ± 0.13

0.25 (0.24, 0.26)a

10,275

Barnett [42]

£

24,737 ± 739

22,362 ± 725

2375

9.18 ± 0.12

9.02 ± 0.11

0.15

15,423

  1. Values in cell are mean ± standard deviation, a95% CI, ΔC incremental cost, ΔE incremental QALY, GLP1a Glucagon-like peptide 1 agonists, DPP4i Dipeptidyl peptidase-4 inhibitors